Human LTBR ELISA Matched Antibody Pair

The cytokines lymphotoxin (LT) alpha, beta and their receptor (LT beta R) belong to the tumor necrosis factor (TNF) superfamily, whose founder-TNF alpha-was initially discovered due to its tumor necrotizing activity. LT beta R signaling serves pleiotropic functions including the control of lymphoid organ development, support of efficient immune responses against pathogens due to maintenance of intact lymphoid structures, induction of tertiary lymphoid organs, liver regeneration or control of lipid homeostasis. Signaling through LTbR comprises the noncanonical/canonical nuclear factor-kappa B (NF-kappa B) pathways thus inducing chemokine, cytokine or adhesion molecule expression, cell proliferation and cell survival. Blocking LT beta R signaling or Fc gamma-receptor mediated immunoablation of LT-expressing cells was demonstrated to be beneficial in various infectious or noninfectious inflammatory or autoimmune disorders. Only recently, LT beta R signaling was shown to initiate inflammation-induced carcinogenesis, to influence primary tumorigenesis and to control reemergence of carcinoma in various cancer models through distinct mechanisms. Indeed, LT beta R signaling inhibition has already been used as efficient anti-inflammatory, anti-cancer therapy in some experimental models. Here, we review the pleiotropic functions attributed to LT, the effects of its deregulation and extensively discuss the recent literature on LT's link to carcinogenesis. Oncogene (2010) 29, 5006-5018; doi:10.1038/onc.2010.260; published online 5 July 2010

This study addressed the clinical characteristics, treatment, and outcome of middle ear cancer. A series of 33 patients with middle ear cancer were analyzed with survival, the primary outcome. Altogether, 25 patients underwent surgery with adjuvant radiotherapy, seven patients had surgery alone, and one patient had only radiotherapy. The patients were staged according to the Stell staging system. Among patients with T-1/T-2 cancers, five underwent lateral temporal bone resection (LTBR) and three underwent subtotal temporal bone resection (STBR). Among those with T-3/T-x cancers, 11 underwent LTBR, and 13 had STBR. Of the total 33 patients, 18 died of their disease during follow-up. The overall 5-year survival rate was 37.4 %. The 5-year survival rates for patients with T-1/T-2 disease and T-3/T-x disease were 85.7 and 22.0 %, respectively. There was a statistically significant difference in 5-year survival rates between the two groups using the log-rank test (P < 0.05). The 5-year survival rates after LTBR and STBR for the T-3/T-x group were 15.2 and 30.8 % (P > 0.05), respectively, and those for the T-1/T-2 group were 100 and 66.7 % (P > 0.05), respectively. The 5-year survival rates for patients who underwent preoperative or postoperative radiotherapy were 38.9 and 40.4 %, respectively (P > 0.05). En bloc resection is favored in an effort to produce negative surgical margins for middle ear cancer. Adjunctive radiotherapy is used for advanced lesions.